Nicholas Lydon
Founder at BLUEPRINT MEDICINES CORPORATION
Net worth: 5 M $ as of 2024-04-29
Profile
Nicholas B.
Lydon was the founder of AnaptysBio, Inc. (founded in 2005) where he served as Director from 2005 to 2010.
He was also the founder of Kinetix Pharmaceuticals, Inc. (founded in 1997) where he held the title of President & Chief Executive Officer from 1997 to 2000.
In addition, he is the founder of Blueprint Medicines Corp.
(founded in 2008) where he currently serves as an Independent Director.
He is also the founder of Granite Biopharma LLC (founded in 2003) where he is a Member.
Furthermore, he founded Recludix Pharma, Inc. (founded in 2019) and served as Chairman from 2019 to 2022.
Dr. Lydon is also the founder of IDRx, Inc...
Dr. Lydon's current job is as a Managing Member at Staurus Pharma LLC since 2011.
His former positions include being a Director at Ambit Biosciences Corp.
from 2004 to 2009, Vice President-Small Molecule Drug Discovery at Amgen, Inc. from 2000 to 2002, and a Principal at Schering-Plough Corp.
He also worked as a Principal at Ciba-Geigy AG from 1985 to 1996.
Dr. Lydon's education includes an undergraduate degree from the University of Leeds and a doctorate degree from the University Of Dundee.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-30 | 53,184 ( 0.09% ) | 5 M $ | 2024-04-29 |
Nicholas Lydon active positions
| Companies | Position | Start |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Founder | 2008-09-30 |
Granite Biopharma LLC
 Granite Biopharma LLC Miscellaneous Commercial ServicesCommercial Services Granite Biopharma LLC provides consulting services. The private company is based in Wilson, WY. The company was founded by Nicholas B. Lydon. | Founder | 2002-12-31 |
| Staurus Pharma LLC | Corporate Officer/Principal | 2010-12-31 |
Former positions of Nicholas Lydon
| Companies | Position | End |
|---|---|---|
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Founder | 2022-09-12 |
| AMBIT BIOSCIENCES CORP | Director/Board Member | 2008-12-31 |
| AMGEN INC. | Corporate Officer/Principal | 2002-01-01 |
Kinetix Pharmaceuticals, Inc.
 Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Chief Executive Officer | 2000-11-30 |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | 1996-12-30 |
Training of Nicholas Lydon
| University of Leeds | Undergraduate Degree |
| University Of Dundee | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private companies | 8 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
Kinetix Pharmaceuticals, Inc.
Kinetix Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kinetix Pharmaceuticals develops selective protein kinase inhibitors which block disease-causing pathways resulting from aberrant protein kinase activity | Commercial Services |
Granite Biopharma LLC
Granite Biopharma LLC Miscellaneous Commercial ServicesCommercial Services Granite Biopharma LLC provides consulting services. The private company is based in Wilson, WY. The company was founded by Nicholas B. Lydon. | Commercial Services |
| Staurus Pharma LLC | |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
IDRx, Inc.
 IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Nicholas Lydon
